EIR-1003
Glaucoma, Neovascular Glaucoma, Proliferative Diabetic Retinopathy
Key Facts
About EIR Biopharma
EIR Biopharma, founded in 2019 and based in San Diego, is pioneering a novel therapeutic approach centered on modulating the Ephrin receptor, a key regulator of cellular guidance, survival, and angiogenesis. Its lead asset, EIR-1003, is a small molecule antagonist in preclinical development for glaucoma and other ocular diseases, with a secondary program, EIR-0205, for Stargardt disease. The company leverages partnerships with top academic institutions and is led by a team with extensive biopharma experience, aiming to build a pipeline-in-a-mechanism platform that extends beyond ophthalmology into major disease areas with high unmet need.
View full company profileAbout EIR Biopharma
EIR Biopharma, founded in 2019 and based in San Diego, is pioneering a novel therapeutic approach centered on modulating the Ephrin receptor, a key regulator of cellular guidance, survival, and angiogenesis. Its lead asset, EIR-1003, is a small molecule antagonist in preclinical development for glaucoma and other ocular diseases, with a secondary program, EIR-0205, for Stargardt disease. The company leverages partnerships with top academic institutions and is led by a team with extensive biopharma experience, aiming to build a pipeline-in-a-mechanism platform that extends beyond ophthalmology into major disease areas with high unmet need.
View full company profile